Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.

By I. Flinn, R. Van der Jagt, B. Kahl, P. Wood, T. Hawkins, D. Macdonald, M. Hertzberg, Y. Kwan, D. Simpson, M. Craig and 7 more. Blood, 2014

627 citations recorded by the source corpus.

Subfields: Genetics, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/145e8cd01e571db46fa2c06f5bf0782c311bcd03

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. M. Maurer
2. John Hainsworth
3. Xiaolei Zhou
4. C. Flowers
5. James R. Cerhan
6. A. Zelenetz
7. J. Friedberg
8. C. Farber

Citations in the corpus

• Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. (2015, background): “R-CHOP, in particular, is one of the most effective treatments currently in use, and it is equivalent to other regimens.(9) The effect of early POD with novel non–chemotherapy-containing regimens will require validation in future studies.”